Overview
- 41 inspections across 39 sites are on record.
- 32 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2026-05-22.
At a glance
Inspections
41
Sites
39
Observations
32
Career since
Jul 2023
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Keun-Wook Lee, M.D., Ph.D. | 22 May 2026 | Human Drugs | On file |
| Sae-Won Han, M.D., Ph.D. | 15 May 2026 | Human Drugs | |
| Avotres Inc. | 24 Apr 2026 | Biologics | On file |
| Omnivium Pharmaceuticals LLC | 27 Mar 2026 | Human Drugs | |
| Merck & Co. Inc | 13 Mar 2026 | Human Drugs |
Sites inspected
Keun-Wook Lee, M.D., Ph.D.Seongnam, Korea (the Republic of)1 insp.
Sae-Won Han, M.D., Ph.D.Jongno, Korea (the Republic of)1 insp.
Avotres Inc.Cedar Knolls, United States1 insp.
Omnivium Pharmaceuticals LLCRahway, United States1 insp.
Merck & Co. IncRahway, United States1 insp.
Co-investigators
Investigators who share inspections with this person.
Michael Serrano9 shared
Tyanna N Hadley3 shared
Agata E Libera1 shared
Sarmistha Sanyal1 shared
Namita Kothary1 shared
Jay B Shah1 shared
Ashley J Burns1 shared
Full investigator report
Get the verbatim findings behind Mayar M Mussa's 32 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site